These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

477 related articles for article (PubMed ID: 25712364)

  • 1. Evolution of hepatitis C virus quasispecies during repeated treatment with the NS3/4A protease inhibitor telaprevir.
    Susser S; Flinders M; Reesink HW; Zeuzem S; Lawyer G; Ghys A; Van Eygen V; Witek J; De Meyer S; Sarrazin C
    Antimicrob Agents Chemother; 2015 May; 59(5):2746-55. PubMed ID: 25712364
    [TBL] [Abstract][Full Text] [Related]  

  • 2. HCV NS3 quasispecies in liver and plasma and dynamics of telaprevir-resistant variants in breakthrough patients assessed by UDPS: A case study.
    Bartolini B; Selleri M; Garbuglia AR; Giombini E; Taibi C; Lionetti R; D'Offizi G; Capobianchi MR
    J Clin Virol; 2015 Nov; 72():60-5. PubMed ID: 26418073
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hepatitis C virus NS3 protease genotyping and drug concentration determination during triple therapy with telaprevir or boceprevir for chronic infection with genotype 1 viruses, southeastern France.
    Aherfi S; Solas C; Motte A; Moreau J; Borentain P; Mokhtari S; Botta-Fridlund D; Dhiver C; Portal I; Ruiz JM; Ravaux I; Bregigeon S; Poizot-Martin I; Stein A; Gérolami R; Brouqui P; Tamalet C; Colson P
    J Med Virol; 2014 Nov; 86(11):1868-76. PubMed ID: 25052594
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Exploring resistance pathways for first-generation NS3/4A protease inhibitors boceprevir and telaprevir using Bayesian network learning.
    Cuypers L; Libin P; Schrooten Y; Theys K; Di Maio VC; Cento V; Lunar MM; Nevens F; Poljak M; Ceccherini-Silberstein F; Nowé A; Van Laethem K; Vandamme AM
    Infect Genet Evol; 2017 Sep; 53():15-23. PubMed ID: 28499845
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Analysis of long-term persistence of resistance mutations within the hepatitis C virus NS3 protease after treatment with telaprevir or boceprevir.
    Susser S; Vermehren J; Forestier N; Welker MW; Grigorian N; Füller C; Perner D; Zeuzem S; Sarrazin C
    J Clin Virol; 2011 Dec; 52(4):321-7. PubMed ID: 21924672
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Deep sequencing and phylogenetic analysis of variants resistant to interferon-based protease inhibitor therapy in chronic hepatitis induced by genotype 1b hepatitis C virus.
    Sato M; Maekawa S; Komatsu N; Tatsumi A; Miura M; Muraoka M; Suzuki Y; Amemiya F; Takano S; Fukasawa M; Nakayama Y; Yamaguchi T; Uetake T; Inoue T; Sato T; Sakamoto M; Yamashita A; Moriishi K; Enomoto N
    J Virol; 2015 Jun; 89(11):6105-16. PubMed ID: 25810555
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Resistance Analyses of HCV NS3/4A Protease and NS5B Polymerase from Clinical Studies of Deleobuvir and Faldaprevir.
    Berger KL; Sarrazin C; Nelson DR; Scherer J; Sha N; Marquis M; Côté-Martin A; Vinisko R; Stern JO; Mensa FJ; Kukolj G
    PLoS One; 2016; 11(8):e0160668. PubMed ID: 27494410
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Deep-sequencing analysis of the gene encoding the hepatitis C virus nonstructural 3-4A protease confirms a low prevalence of telaprevir-resistant variants at baseline and the end of the REALIZE study.
    Dierynck I; Thys K; Ghys A; Sullivan JC; Kieffer TL; Aerssens J; Picchio G; De Meyer S
    J Infect Dis; 2014 Dec; 210(12):1871-80. PubMed ID: 24943725
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evolution of treatment-emergent resistant variants in telaprevir phase 3 clinical trials.
    Sullivan JC; De Meyer S; Bartels DJ; Dierynck I; Zhang EZ; Spanks J; Tigges AM; Ghys A; Dorrian J; Adda N; Martin EC; Beumont M; Jacobson IM; Sherman KE; Zeuzem S; Picchio G; Kieffer TL
    Clin Infect Dis; 2013 Jul; 57(2):221-9. PubMed ID: 23575197
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dynamic hepatitis C virus genotypic and phenotypic changes in patients treated with the protease inhibitor telaprevir.
    Sarrazin C; Kieffer TL; Bartels D; Hanzelka B; Müh U; Welker M; Wincheringer D; Zhou Y; Chu HM; Lin C; Weegink C; Reesink H; Zeuzem S; Kwong AD
    Gastroenterology; 2007 May; 132(5):1767-77. PubMed ID: 17484874
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phenotypic characterization of resistant Val36 variants of hepatitis C virus NS3-4A serine protease.
    Zhou Y; Bartels DJ; Hanzelka BL; Müh U; Wei Y; Chu HM; Tigges AM; Brennan DL; Rao BG; Swenson L; Kwong AD; Lin C
    Antimicrob Agents Chemother; 2008 Jan; 52(1):110-20. PubMed ID: 17938182
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical relevance of the HCV protease inhibitor-resistant mutant viral load assessed by ultra-deep pyrosequencing in treatment failure.
    Mohamed S; Bourliere M; Benali S; Oules V; Castellani P; Khiri H; Camus C; Penaranda G; Chiche L; Gonzalez D; Sayada C; Olive D; Halfon P
    J Clin Virol; 2016 May; 78():36-43. PubMed ID: 26971166
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Characterization of telaprevir treatment outcomes and resistance in patients with prior treatment failure: results from the REALIZE trial.
    De Meyer S; Dierynck I; Ghys A; Beumont M; Daems B; Van Baelen B; Sullivan JC; Bartels DJ; Kieffer TL; Zeuzem S; Picchio G
    Hepatology; 2012 Dec; 56(6):2106-15. PubMed ID: 22806681
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hepatitis C viral evolution in genotype 1 treatment-naïve and treatment-experienced patients receiving telaprevir-based therapy in clinical trials.
    Kieffer TL; De Meyer S; Bartels DJ; Sullivan JC; Zhang EZ; Tigges A; Dierynck I; Spanks J; Dorrian J; Jiang M; Adiwijaya B; Ghys A; Beumont M; Kauffman RS; Adda N; Jacobson IM; Sherman KE; Zeuzem S; Kwong AD; Picchio G
    PLoS One; 2012; 7(4):e34372. PubMed ID: 22511937
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antiviral therapy of hepatitis C in 2014: do we need resistance testing?
    Schneider MD; Sarrazin C
    Antiviral Res; 2014 May; 105():64-71. PubMed ID: 24583028
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Kinetics of hepatitis C virus RNA decay, quasispecies evolution and risk of virological failure during telaprevir-based triple therapy in clinical practice.
    Cento V; Tontodonati M; Di Maio VC; Bellocchi MC; Valenti F; Manunta A; Fortuna S; Armenia D; Carioti L; Antonucci FP; Bertoli A; Trave F; Cacciatore P; Angelico M; Navarra P; Neumann AU; Vecchiet J; Parruti G; Babudieri S; Perno CF; Ceccherini-Silberstein F
    Dig Liver Dis; 2015 Mar; 47(3):233-41. PubMed ID: 25637450
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Emergence of telaprevir-resistant variants detected by ultra-deep sequencing after triple therapy in patients infected with HCV genotype 1.
    Akuta N; Suzuki F; Seko Y; Kawamura Y; Sezaki H; Suzuki Y; Hosaka T; Kobayashi M; Hara T; Kobayashi M; Saitoh S; Arase Y; Ikeda K; Kumada H
    J Med Virol; 2013 Jun; 85(6):1028-36. PubMed ID: 23588728
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vitro phenotypic characterization of hepatitis C virus NS3 protease variants observed in clinical studies of telaprevir.
    Jiang M; Mani N; Lin C; Ardzinski A; Nelson M; Reagan D; Bartels D; Zhou Y; Nicolas O; Rao BG; Müh U; Hanzelka B; Tigges A; Rijnbrand R; Kieffer TL
    Antimicrob Agents Chemother; 2013 Dec; 57(12):6236-45. PubMed ID: 24100495
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dynamic changes in HCV RNA levels and viral quasispecies in a patient with chronic hepatitis C after telaprevir-based treatment.
    de Bruijne J; Sullivan JC; Kieffer TL; Botfield M; Shames B; Schinkel J; Molenkamp R; Weegink C; Reesink H
    J Clin Virol; 2012 Feb; 53(2):174-7. PubMed ID: 22138301
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Significance of hepatitis C virus baseline polymorphism during the antiviral therapy].
    Tornai I
    Orv Hetil; 2015 May; 156(21):849-54. PubMed ID: 26038992
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.